Article

1

20

21 22

23

26

39

40

41

42

Early transfusion of convalescent plasma improves the clinical

outcome in severe SARS-CoV2 infection

- 4 Eszter Fodor 1,8,*, Veronika Müller², Zsolt Iványi³, Tímea Berki¹¹, Kuten Pella Olga¹, Mira Ambrus², Ágnes Sárkány⁵,
- 5 Árpád Skázel⁵, Ágnes Madár⁸, Dorottya Kardos¹¹, Gábor Kemenesi⁴, Fanni Földes⁴, Sándor Nagy⁶, Andrea
- 6 Matusovits 6, Nacsa János6, AttilaTordai9 Ferenc Jakab4, Zsombor Lacza1.7.8
- 7 ¹Orthosera Kft, Budapest, 1149, Hungary; <u>eszter.fodor@orthosera.com</u>, olga.kuten@orthoser.com
 - ²Semmelweis University, Department of Pulmonology, Budapest, 1083, Hungary; muller.veronika@med.semmelweis-univ.hu
- 9 3Semmelweis University, Department of Anesthesiology and Intensive Therapy, Budapest, 1082 Hungary; ivanyizs@gmail.com
- 10 ⁴Univesity of Pécs, Szentágothai Research Center, National Laboratory of Virology, Pécs, 7622, Hungary ; <u>jakab.ferenc@pte.hu</u>.
- l 1 <u>fanni4444@gmail.com</u>, kemenesi.gabor@gmail.com
- 12 Szent György University Teaching Hospital, Székesfehérvár, 8000, Hungary; skazelarpad@gmail.com, asarkany1@gmail.com
- 13 ⁶Hungarian National Blood Transfusion Service, Budapest, 1113, Hungary; nagy.sandor@ovsz.hu, foigazgato@ovsz.hu, nacsa.janos@ovsz.hu
- 14 ⁷Semmelweis University, Department of Translational Medicine, 1085, Budapest, Hungary; zsombor.lacza@orthosera.com
- 15 *Univesity of Physical Education, Budapest, 1223, Hungary; agnes.madar@orthosera.com, mira.abrus@tf.hu
- 16 9 Semmelweis University, Department of Transfusiology, Budapest, 1089, Hungary; tordai.attila@med.semmelweis-univ.hu
- 17 ¹⁰University of Pécs, Department of Immunology and Biotechnology, Budapest, 7643, Hungary; berki.timea@pte.hu
- 18 ¹¹Research Center Natural Sciences, Budapest, 1117, Hungary; <u>dorottya333@gmail.com</u>
 - *Correspondence: eszter.fodor@orthosera.com; Tel.: +36306640494
 - **Conflicts of Interest:** The authors declare no conflict of interest. Zsombor Lacza owns stock in OrthoSera kft, a startup company developing the hyperacute serum technology towards clinical application.
- Financial Disclosure statement: All authors declare that there is no financial interests related to the material in the manuscript.
- 27 Abstract: Plasma harvested from convalescent COVID-19 patients (CCP) has been applied as first-line therapy in the
- 28 early phase of the SARS-CoV2 pandemic through clinical studies using various protocols. We present data from a
- 29 cohort of 267 hospitalized, severe COVID-19 patients who received CCP. No transfusion-related complications were
- 30 reported, indicating the overall safety of CCP therapy. Patients who eventually died from COVID-19 received CCP
- 31 significantly later (3.95 versus 5.22 days after hospital admission) and had higher interleukin 6 (IL-6) levels (28.9
- 32 pg/ml versus 102.5 pg/ml) than those who survived. In addition, CCP-transfusion caused a significant reduction in the
- 33 overall inflammatory status of the patients regardless of the severity of disease or outcome, as evidenced by
- decreasing C-reactive protein, IL6 and ferritin levels. We conclude that, CCP-transfusion is a safe and effective
- 35 supplementary treatment modality for hospitalized COVID-19 patients characterized by better expected outcome if
- 36 applied as early as possible. We also observed that, IL-6 may be a suitable laboratory parameter for patient selection
- and monitoring of CCP therapy effectiveness.
- 38 Keywords: convalescent plasma, Interleukin-6, SARS2-CoV, COVID-19

1. Introduction

Severe acute respiratory syndrome caused by the novel coronavirus SARS-CoV2 has been responsible for an unprecedented world pandemic starting out from Vuhan (China) in January 2020. This represented an extraordinary

challenge for the health care systems and entire societies of the developed countries [1,2] including Hungary [3]. The

SARS-CoV2-induced COVID-19 disease is characterized by acute viral pneumonia associated with progressive respiratory insufficiency, requiring oxygen supplementation in about 15% and mechanical ventilation in 5% of the cases with reported overall mortality rates of 2.3% [4,5]. Since SARS-CoV2 is a new human pathogen, initially neither vaccines nor effective therapeutic modalities were available. With several earlier attempts of antiviral passive immunotherapy, COVID-19 convalescent plasma (CCP) therapy has quickly become a readily available and promising therapeutic modality against severe COVID-19 [6,7]. Given the large amount of clinical experience with allogeneic plasma transfusions and the relative lack of potential side effects, regulatory agencies have quickly granted permissions for several parallel clinical trials with CCP [8–10]. After CCP transfusion, virus neutralization antibodies represent the most important mode of action but moderating the unnecessarily severe immune reaction by several soluble factors has also been proposed [11–13]. Apart from the multitude of case studies, initial reports of CCP clinical studies on sizeable cohorts have not been able to demonstrate significant improvements in mortality rates [14-17]. In contrast, in subsequent studies, mortalitybenefits were documented among unselected, severe COVID-19 patients after CCP-transfusions in the USA [18–21], in China [22,23], in India [24], in Europe [25,26] and among selected patients based on risk factors [27,28]. In addition, a potential benefit was also observed in a meta-analysis[29]. Development of severe COVID-19 associated respiratory disease was significantly less frequent after CCP transfusion administered within 72 hours of onset of mild COVID-19 infection compared to a randomized control group [30]. In an early meta-analyzes, low to moderate evidence indicated a lacking benefit [31], a later systematic compilation covering more than 35,000 CCP-treated cases indicated a significantly reduced odds ratio for all-cause mortality associated with CCP-transfusion [29]. Thus, outcome observations after CCP therapies are controversial due to the difficulties to form and analyze homogenous patient cohorts and control groups, the diverse availability of other therapeutic modalities and the substantial differences in local clinical practices. Most studies aimed at reducing mortality rates, however, this required a large number of recruited patients and homogenous treatment groups, which was seldom the case. However, quantitative laboratory parameters may serve as secondary endpoints and provide information on individual patients and also on potential patient selection criteria for future studies. Our earlier experience with blood plasma-based therapies has also

2. Materials and Methods

transfusions in severe COVID-19 patients.

Study description

43

44

45

46

47

48

49

50

51

52

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82 83

84

85

86

The trial was designed in accordance with WHO (2015 WHO/HIS/KER/GHE/15.1) as an open-label, prospective, interventional study and approved by the Hungarian National Medical Research Council (approval number: IV/3457/2-2020-EKU) and registered in ClinicalTrials.gov (NCT04345679). Due to ethical concerns of leaving any patient untreated or placebo-treated (e.g., non-convalescent fresh frozen plasma), no control arm was included. The primary clinical endpoint was patient survival, secondary endpoints were the time of convalescent plasma administration (days from hospital admission), the duration of hospital stay (days), the mortality rate (% of patients), the hematological laboratory parameter WBC, and inflammatory markers such as ferritin, C-reactive protein (CRP) and interleukin-6 (IL-6).

provided evidence that measuring cytokine levels may be informative in monitoring the effectiveness of blood-based

therapies [32,33]. Thus, the aim of the current study to analyze the outcome and immunology parameters after CCP-

Plasma donation

Plasma was collected from healthy voluntary convalescent donors of both sexes aged 18-65 years, with confirmed previous SARS-CoV2 infection. A positive result of either SARS-CoV2 PCR or antigen screening test at the time of plasma donation was a reason for exclusion. Donors were required to meet all eligibility requirements valid

for regular blood donors. An inclusion criterion was a positive IgG antibody level (>24 U/ml) against SARS-CoV2 nucleocapsid protein (measured by Microgen semi-quantitative ELISA assays). To decrease the risks of TRALI (transfusion-related acute lung injury), all female donors were screened for anti-HLA antibodies, and positive donors were excluded from plasma donation. Altogether 400 ml of convalescent plasma was collected from donors through an automated plasma apheresis separator. The Hungarian National Blood Service divided the 400 ml plasma into two therapeutic doses of 200 ml. Plasma products underwent pathogen reduction and irradiation. The processed plasma was stored at -20°C until used. ABO compatibility was strictly observed throughout the study.

Recipients

 Convalescent plasma recipients were hospitalized patients of both sexes and ages admitted to a University hospital COVID ward between April 2020 and February 2021 and who were suitable for receiving plasma judged by their attending physicians.

<u>Laboratory measurements</u>

Laboratory hematological parameters were measured with clinical hematology analyzers. Ferritin and C-reactive protein levels were measured before and on days 1 and 7 after plasma transfusion. White blood cell count was determined before and on days 1 and 2 after plasma transfusion. Levels of the pro-inflammatory cytokine interleukin-6 (IL-6) were measured before and on days 1 and 7 with electrochemiluminescence immunoassay (ECLIA).

Simple Plex cytokine assay

IL-1 beta, IL-6, IL-8 and TNF alpha concentrations were analyzed in plasma from 21 selected COVID-19 patients with Simple Plex assays run on the EllaTM automated immunoassay analyzer (ProteinSimple, San Jose, CA). Diluted (1:2) plasma samples together with buffer were loaded into the ELLA cartridge and measured according to the manufacturer's instruction.

Statistical analysis

- 15 Data were analyzed with the two-tailed Mann-Whitney test and Fisher's exact test using GraphPad Prism software.
- 16 P<0.05 was considered significant.

3. Results

3.1 Patient characteristics

- 22 The key characteristics and laboratory findings of 267 patients can be found in Table 1. Data distribution was spread
- 23 on a wide scale, demonstrated in histograms of Fig.1. The median of patients' age was 67 years, with a median
- 24 hospitalization time of 15 days. Over 90% of patients had serious co-morbities and had markedly elevated
- 25 inflammatory parameters before CCP-treatment (Table 1). 76% of patients were admitted to the COVID ward (CW)
- and 24% to the ICU.
- 27 After comparing patients from CW and ICU a statistical relationship between age, sex, hospitalization time, mortality,
- WBC, ferritin and CRP level was found. The median age of patients admitted to the ICU was lower (63 years) than
- 29 that of CW patients (69 years) and 74% of ICU patients were male. As expected, WBC, ferritin and CRP levels on the

day of admission were significantly higher in the ICU patient group. Also, ICU patients had longer hospitalization time but the median number of days to CCP therapy was the same in both groups. No significant association with CW/ICU admission and the time until CCP therapy, chronic illness and IL-6 level was observed. Since the decision on whether a patient is treated at the ICU was based on multiple factors partly unrelated to their COVID-19 status, e.g., co-morbidities or place availability, and that there was no difference in the treatment regimens regarding plasma therapy or the inflammatory parameters between the CW and the ICU subgroups, the subsequent analyzes are presented as a single group of patients.

Table.1 Baseline characteristics of COVID-19 positive patients selected for CCP therapy. Patients' parameters have been calculated for the whole group (n=267) and for COVID ward and ICU patients. Data were analyzed with Fisher's exact test.

	All patients n=267	COVID ward (n=202)	ICU (n=65)	P (< 0.05 significant)
Age(years, median)	67	69	63	0,0103
Sex, n (%)	female 40%	female 45%	female 26%	0,0089
	male 60%	male 55%	male 74%	
Hospitalization time (days, median)	15	14	17	0,0202
Time until CCP therapy (days, median)	3	3	3	0,8087, ns
Hypertension, n (%)	63,5%	49,5%	49%	0,2959, ns
Diabetes, n (%)	25,5%	22,3%	12%	0,1833, ns
Cancer active, n (%)	11,5%	10,4%	5,3%	0,3014, ns
Other chronic illness	21,2%	10,5%	6,1%	0,4626, ns
No chronic illness	9,1%	7,4%	6,1%	1, ns
Not known (no documentation about chronic illness)	22,1%	19%	29%	7.0
Recovered, n (%)	68,5%	77,7%	40%	P<0.0001
Deceased, n (%)	31,5%	22,3%	60%	
WBC (G/I), mean (day 1)	9,8	8,7	13,4	0,0010
Ferritin (ng/ml), mean (day 1)	1296	1026	2121	0,0003
CRP (mg/L), mean (day 1)	111,5	103,7	136,6	0,0090
IL-6 (pg/ml), mean (day1)	77,5	82.68	34.06	0,1452, ns

.37




Fig.1 Histograms presenting the distribution of age, hospitalization time, time before CCP, and the levels of WBC, ferritin, CRP and IL-6 on day 1. The total number of patients analysed was 267, however, when laboratory tests were not performed on a given day data was excluded. Documentation about WBC level was available for n=158 patients, about ferritin for n=126 patients, about CRP for n=187 patients and about IL-6 for n=104 patients. Nonetheless, all statistical comparisons were adequately powered.

3.2 Administration of CCP to COVID patients

CCP transfusion was safe with no grade 3 adverse events reported. To identify the best time point when CCP should be administrated, the hospitalization time before CCP therapy was compared between the deceased and recovered patients (Fig.2). Frequency distribution analysis revealed that CCP therapy was applied earlier in patients who eventually recovered than in those who deceased, with a significant difference (P= 0,0133) between the time of CCP therapy between the survivors (3,95 days) and deceased patients (5,22 days) (Fig. 2). Based on this observation, we regrouped the patients to those who received CCP up to 3 days after hospitalization and compared their survival rate to those that received CCP at day 4 or later time points in their respective treatment regimes. Indeed, the mortality rate was significantly lower (P= 0,0226) among patients who received CCP up to 3 days after hospital admission (24%) versus patients who received it later (40%) (Fig. 2).




Fig. 2 Time until CCP therapy in hospitalized patients. Panels A and B show histograms of time until CCP therapy in days from hospitalization in survivors and decedents, respectively. Panel C shows the mean ± SEM values of hospitalization time before CCP for recovered and deceased patients, asterisk indicates p<0.05 with Mann-Whitney test. Panel D shows that patients who received plasma during the first 3 days of hospitalization had a significantly

better survival rate than those who received CCP therapy at later timepoints, asterisk indicates P<0.05 with Fisher's exact test.

3.3 Effect of CCP therapy on inflammatory parameters

To identify the reliable prognostic factors for COVID patient's recovery, IL-6, IL-1 beta, IL-8 and TNF alpha was additionally analyzed from the available frozen serum samples of 21 patients (Fig.3). IL-1 beta (deceased 0,5 pg/ml, recovered 0,6 pg/ml), IL-8 (deceased 31,3 pg/ml, recovered 22,5 pg/ml) and TNF alpha concentration (deceased 21,1 pg/ml, recovered 16,1 pg/ml), were not above the physiological level (minimum-maximum values of cytokines levels in healthy controls according to the literature are 0,0-5,0 pg/ml for IL-1 beta [34]; 0,0–50,4 pg/ml for IL-8 [35] and 0,0–32,5 pg/ml for TNF alpha [35]). Also, the changes of these cytokine levels were not significant between recovered and deceased patients (Fig. 3). At the same time, IL-6 concentration was clearly above the normal level for healthy individuals (0.0–12.7 pg/mL [35]) before plasma therapy and patients who died during hospitalization had significantly higher (P= 0,0066) IL-6 levels than survivors (deceased 102,5 pg/ml, recovered 28,9 pg/ml, Fig. 3).




Fig.3 IL-6, IL-1 beta, IL-8 and TNF alpha levels in survivors and decedents blood harvested before CCP therapy (n=21 patients). Normal range is indicated with a greyed area on each panel. Data are represented as average \pm SEM, asterisk indicates P<0.05 with Mann-Whitney's test.

The level of ferritin, CRP and IL-6 was compared between blood samples collected before and after CCP therapy to assess if there was an improvement of patients' condition. All three parameters were significantly lower (ferritin P= 0,0025; CRP and IL-6 P<0.0001) after plasma administration (Fig. 4).




Fig.4. IL-6, CRP and ferritin levels before and after CCP. Documentation about the ferritin level before and after CCP was available for n=79 patients, about CRP for n=130 patients and IL-6 for n=58 patients. Data are presented as average \pm SEM, ** indicates P<0.01, *** indicates P<0.001 with Mann-Whitney's test.

4. Discussion

!14

:17

In the current study, we systematically monitored selected outcome parameters in a sizeable cohort of severe COVID-19 patients who received CCP therapy as a supplementary intervention besides standard supportive and causative therapies. As expected, several baseline characteristics showed significant differences upon comparing those patients who were treated on the COVID ward versus those under intensive care reflecting the different severity of their overall clinical status. In agreement with other reports [24], males were over-represented in the ICU-subgroup, along with elevated WBC, ferritin and CRP levels. A high proportion of patients had severe co-morbidities that clearly affected their treatment needs in addition to their COVID19 status, therefore, it is not justified to separate the cohort into subgroups based on any variable singled out from a multitude of parameters.

We addressed the importance of initiation timepoint of CCP transfusions by using the indicator of number of days elapsing in the hospital prior to CCP therapy. In such comparison, significantly longer time elapsed in the deceased subgroup compared to survivors. Moreover, dichotomizing the entire patient group according to the median value of days until CCP-therapy with 3 days as a threshold, showed significantly higher proportion of deceased patients in the subgroup characterized by longer than 3 days. Supporting the importance of early application of CCP therapy comes from a prospective USA study indicating significant mortality reduction compared to matched control cases only in the subgroup receiving CCP transfusion within 72 hours of hospital admission [20]. In a smaller comparative study CCP-transfusion within 72 hours from hospital admission was more efficient among patients aged less than 65 years [19]. In another smaller study a similar benefit of earlier application of CCP-therapy was observed with improvements of several clinical outcomes associated with CCP-administration before 7 days from diagnosis [26]. Furthermore, in an outstanding randomized, double-blind, placebo-controlled trial performed in Argentina, development of COVID-19-associated predefined severe respiratory disease was significantly less frequent in the treated group receiving CCP transfusion within 72 hours from the onset of mild COVID-19 in an elderly population [30]. The importance of appropriate timing of CCP-transfusions as well as careful candidate selection instead of the compassionate use of CCP has clearly been emphasized in an editorial [36].

Considering the relative paucity of information on inflammatory cytokine levels in CCP-treated COVID-19-patients, in a subgroup of our cohort, we included baseline and follow-up measurements of critical cytokine levels such as IL-6, IL-8, TNF-alpha and IL-1-beta. Comparing baseline levels between recovered and deceased patients, we observed that IL-6 was the only inflammatory cytokine characterized by significantly elevated baseline levels among the deceased CCP-treated patients indicating a potential role of this inflammatory cytokine as a prognostic marker. In

another comparison addressing marker status before and after CCP-transfusion, similarly to general inflammatory markers, IL-6 levels showed significant decreases. This observation is in line with those of others and suggests a putative immunomodulatory effect exerted by CCP [11]. In particular, in smaller study, besides IL-6, additionally TNF-alpha and IFN-gamma levels also showed significant decreases while that of IL-10 increased following CCP-therapy [37]. In the framework of another randomized trial of CCP therapy, Il-6 serum levels decreased along with those of interferon gamma induced protein 10 in response to CCP-transfusion [38]. However, it should be noted that, the possible connection of IL-6 levels with the therapeutic effect of CCP does not mean a causal relationship in either way, and further studies are needed to identify the molecular-level interactions between IL-6-involving inflammatory mechanisms. It is also noteworthy that, convalescent plasma is also a source of a number of interleukins and cytokines that are administered alongside the anti-SARS2-CoV neutralizing antibodies.

222

223

224

225

226

227

228

:29

!30

231

!32

233

234

235

236

!37

138

!39

240

241

242

:43

244

245

246

253

Limitations of the current study include its non-controlled design, its limited sample size and partial unavailability of samples for detailed immunological testing in a significant proportion of the patients included. Prehospital history of the patients was not accessible leaving room for variation in SARS2-CoV2 infection periods. In light of all the above limitations, we believe that our observations should rather be viewed as an indicator prompting further studies with improved design targeting special features of CCP therapy such as early intervention in patients with only moderate IL-6 levels. Comparing results of the large number of registered clinical trials (n=164 on ClinicalTrials.gov at the time of writing) may help to identify critical factors in study design and patient selection to obtain benefits of clinical outcome after CCP in severe COVID-19, however, this future effort will depend on original study data to become available.

In conclusion, our results indicate that CCP transfusion is a safe supplementary option that can easily be incorporated into the complex therapeutic scheme of severe COVID-19 patients. Early timing of CCP transfusion is clearly preferable. CCP transfusion resulted in significant decreases in inflammatory markers and pretransfusion measurements of these markers may allow further stratification of severe COVID-19 patients amenable for efficient CCP therapy.


- Author Contributions: Conceptualization, Zsombor Lacza and Eszter Fodor and Olga Kuten.; methodology, Veronika Müller, validation, Ferenc Jakab, Gábor Kemenesi, Fanni Földes, formal analysis, Ágnes Madár, Mira Ambrus and Dorottya Kardos; investigation, Zsolt Iványi.; data curation, Eszter Fodor and Attila Tordai, János Nacsa; writing—150 original draft preparation, Zsombor Lacza, Olga Kuten; writing—review and editing, supervision, Attila Tordai, Zsombor Lacza, Eszter Fodor, Tímea Berki; project administration, Árpád Skázel, resources, Sándor Nagy, Andrea Matusovits, Ágnes Sárkány
- 1.54 **Funding:** This research was funded by the Ministry for Innovation and Technology and the grant numbers are the following: K135757 and 2020-1.1.6-JÖVŐ-2021-00010. 4
- 156 Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of 157 Helsinki, and approved by the Hungarian National Ethics Comittee (protocol code 1943-6/2020/EÜIG and date of 158 approval: 2020.04.15).
- 1.59 Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
- 260 Acknowledgments: This work was partially supported by the Higher Education Institutional Excellence Program
- !61 (FIKP) of the Ministry for Innovation and Technology, within the framework of the Molecular Biology thematic
- .62 program of the Semmelweis University as well as by grants from the National Research, Development and Innovation
- 263 Fund (NKFI) K135757 and 2020-1.1.6-JÖVŐ-2021-00010. We would like to thank you all the donors, who donated
- 264 convalescent plasma, and all the nurses, doctors and health care workers who made this treatment possible.


- '.65 Conflicts of Interest: The authors declare no conflict of interest. Zsombor Lacza owns stock in OrthoSera kft, a startup
- company developing the hyperacute serum technology towards clinical application.
- 267 References
- 268 1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China.
- .69 N Engl J Med. 2020 Apr 30;382(18):1708–20.
- 2. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting
- 271 Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New
- .'72 York City Area. JAMA J Am Med Assoc. 2020 May 26;323(20):2052–9.
- 273 3. Tordai A, Nagy S, Baróti-Tóth K, Marton I, Lázár M, Demeter J, et al. A SARS-CoV2-járvány hatása a hazai
- vérellátásra. Hematológia–Transzfuziológia. 2020 Sep 12;53(2):96–105.
- 2.75 4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of
- 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507–
- 278 5. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-
- 19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and
- 280 Prevention. Vol. 323, JAMA Journal of the American Medical Association. American Medical Association;
- !81 2020. p. 1239–42.
- 282 6. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19 [Internet]. Vol. 130, Journal
- 283 of Clinical Investigation. American Society for Clinical Investigation; 2020. p. 1545–8.
- 284 7. Abraham J. Passive antibody therapy in COVID-19. Vol. 20, Nature Reviews Immunology. Nature Research;
- 2020. p. 401–3.
- 286 8. Recommendations for Investigational COVID-19 Convalescent Plasma | FDA [Internet].
- 187 9. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020 Mar
- 289 10. Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.
- 290 Vol. 115, Vox Sanguinis. Blackwell Publishing Ltd; 2020. p. 485–7.
- 191 11. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in
- 292 Covid-19: Possible mechanisms of action. Vol. 19, Autoimmunity Reviews. Elsevier B.V.; 2020.
- 193 12. Simon M, Major B, Vácz G, Kuten O, Hornyák I, Hinsenkamp A, et al. The effects of hyperacute serum on the
- elements of the human subchondral bone marrow niche. Stem Cells Int. 2018;2018.
- 195 13. Kardos D, Marschall B, Simon M, Hornyák I, Hinsenkamp A, Kuten O, et al. Investigation of Cytokine
- 296 Changes in Osteoarthritic Knee Joint Tissues in Response to Hyperacute Serum Treatment. Cells. 2019 Aug
- !97 3;8(8).
- 198 14. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to
- .99 Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
- JAMA J Am Med Assoc. 2020 Aug 4;324(5):460–70.
- 101 15. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the
- management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled
- trial (PLACID Trial). BMJ. 2020 Oct 22;371.
- 16. Sostin O V., Rajapakse P, Cruser B, Wakefield D, Cruser D, Petrini J. A matched cohort study of convalescent


- plasma therapy for COVID-19. J Clin Apher. 2021;
- Simonovich VA, Burgos Pratx LD, Scibona P, Beruto M V., Vallone MG, Vázquez C, et al. A Randomized Trial
- of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619–29.
- 18. Shenoy AG, Hettinger AZ, Fernandez SJ, Blumenthal J, Baez V. Early mortality benefit with COVID-19
- convalescent plasma: a matched control study. Br J Haematol. 2021 Feb 1;192(4):706–13.
- 10 19. Yoon H, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH, et al. Treatment of severe COVID-19 with
- convalescent plasma in Bronx, NYC. JCI Insight. 2021 Feb 22;6(4).
- \$12 20. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of Coronavirus Disease
- 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. Am J Pathol.
- 314 2020 Nov 1;190(11):2290–303.
- 15 21. Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on
- mortality among hospitalized patients with COVID-19: Initial three-month experience. medRxiv; 2020. p.
- 117 2020.08.12.20169359.
- 118 22. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe
- COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490–6.
- 320 23. Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, et al. Improved clinical symptoms and mortality among patients
- with severe or critical COVID-19 after convalescent plasma transfusion. Vol. 136, Blood. American Society of
- Hematology; 2020. p. 755–9.
- 123 24. Budhiraja S, Dewan A, Aggarwal R, Singh O, Juneja D, Pathak S, et al. Effectiveness of convalescent plasma in
- Indian patients with COVID-19. Blood Cells, Mol Dis. 2021 May 1;88.
- 125 25. Tworek A, Jaroń K, Uszyńska-Kałuża B, Rydzewski A, Gil R, Deptała A, et al. Convalescent plasma treatment
- is associated with lower mortality and better outcomes in high-risk COVID-19 patients propensity-score
- matched case-control study. Int J Infect Dis. 2021 Apr 1;105:209–15.
- 128 26. Moniuszko-Malinowska A, Czupryna P, Zarębska-Michaluk D, Tomasiewicz K, Pancewicz S, Rorat M, et al.
- Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter
- Study. J Clin Med. 2020 Dec 24;10(1):28.
- 131 27. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of
- severe COVID-19: a propensity score–matched control study. Nat Med. 2020 Nov 1;26(11):1708–13.
- 133 28. Pappa V, Bouchla A, Terpos E, Thomopoulos TP, Rosati M, Stellas D, et al. A phase ii study on the use of
- convalescent plasma for the treatment of severe covid-19-a propensity score-matched control analysis.
- Microorganisms. 2021 Apr 1;9(4).
- 136 29. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of Convalescent
- Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021
- May;96(5).
- 139 30. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early High-Titer Plasma Therapy to
- Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021 Feb 18;384(7):610–8.
- 31. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al. Association of Convalescent Plasma
- Treatment with Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. JAMA
- J Am Med Assoc. 2021 Mar 23;325(12):1185–95.
- 32. Kardos D, Marschall B, Simon M, Hornyák I, Hinsenkamp A, Kuten O, et al. Investigation of Cytokine


345 Changes in Osteoarthritic Knee Joint Tissues in Response to Hyperacute Serum Treatment. Cells 2019, Vol 8, 346 Page 824. 2019 Aug;8(8):824. 347 33. Neubauer M, Kuten O, Stotter C, Kramer K, Luna A De, Muellner T, et al. The Effect of Blood-Derived 348 Products on the Chondrogenic and Osteogenic Differentiation Potential of Adipose-Derived Mesenchymal 149 Stem Cells Originated from Three Different Locations. Stem Cells Int. 2019;2019. 350 34. Iglesias Molli AE, Bergonzi MF, Spalvieri MP, Linari MA, Frechtel GD, Cerrone GE. Relationship between the 351 IL-1β serum concentration, mRNA levels and rs16944 genotype in the hyperglycemic normalization of T2D 352 patients. Sci Rep. 2020 Dec 1;10(1). 153 35. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in 154 patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005 Oct 355 24;2005(5):273-9. 356 36. Katz LM. (A Little) Clarity on Convalescent Plasma for Covid-19. N Engl J Med. 2021 Feb 18;384(7):666-8. 357 37. Pouladzadeh M, Safdarian M, Eshghi P, Abolghasemi H, bavani AG, Sheibani B, et al. A randomized clinical 358 trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. 159 Intern Emerg Med. 2021 Apr 10; 60 38. Bandopadhyay P, Lahiri A, Sarif J, Ray Y, Ranjan Paul S, Roy R, et al. Nature and dimensions of the systemic 61 hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19. 62

163 164









	All patients n=267	COVID ward (n=202)	ICU (n=65)	P (< 0.05 significant)
Age(years, median)	67	69	63	0,0103
Sex, n (%)	female 40%	female 45%	female 26%	0,0089
	male 60%	male 55%	male 74%	
Hospitalization time (days, median)	15	14	17	0,0202
Time until CCP therapy (days, median)	3	3	3	0,8087, ns
Hypertension, n (%)	63,5%	49,5%	49%	0,2959, ns
Diabetes, n (%)	25,5%	22,3%	12%	0,1833, ns
Cancer active, n (%)	11,5%	10,4%	5,3%	0,3014, ns
Other chronic illness	21,2%	10,5%	6,1%	0,4626, ns
No chronic illness	9,1%	7,4%	6,1%	1, ns
Not known (no documentation about chronic illness)	22,1%	19%	29%	-
Recovered, n (%)	68,5%	77,7%	40%	P<0.0001
Deceased, n (%)	31,5%	22,3%	60%	P<0.0001
WBC (G/I), mean (day 1)	9,8	8,7	13,4	0,0010
Ferritin (ng/ml), mean (day 1)	1296	1026	2121	0,0003
CRP (mg/L), mean (day 1)	111,5	103,7	136,6	0,0090
IL-6 (pg/ml), mean (day1)	77,5	82.68	34.06	0,1452, ns